Top Markets
Coin of the day
Ocumension Therapeutics Ocumension Therapeutics

Ocumension Therapeutics

1477
Rank in Stocks #12971
Based in the People's Republic of China, Ocumension Therapeutics functions as a... Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Share Price
$0.66137861
Market Cap
$531.70M
Change (1 day)
-2.45%
Change (1 year)
-42.12%
Country
CN
Trade Ocumension Therapeutics (1477)

Category

P/B ratio for Ocumension Therapeutics (1477)
P/B ratio as of 2026 TTM: 0
According to Ocumension Therapeutics latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Ocumension Therapeutics from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH